Metastatic adenocarcinoma lymph node involvement represents lymphatic spread of solid organ malignancies (lung, breast, colorectal, gastric, pancreatic). Lymph nodes in primary tumor drainage basin are sequentially involved. Unlike SCC metastasis, central necrosis is less common and cystic change is rare. Enhancement pattern varies by primary — hypervascular thyroid or renal cell carcinoma metastasis shows intense enhancement, while colorectal or pancreatic metastasis enhances moderately. Supraclavicular LAP (Virchow node) may indicate distant metastasis of abdominal malignancy. Axillary LAP suggests breast, inguinal LAP genital/lower extremity, mediastinal LAP lung malignancies.
Age Range
40-80
Peak Age
65
Gender
Equal
Prevalence
Common
Adenocarcinoma cells spread from primary tumor to regional lymph nodes via lymphatic channels. Tumor cells first lodge in subcapsular sinus, then infiltrate cortical and medullary areas. Desmoplastic stromal reaction is common in adenocarcinoma metastasis — this fibrotic response causes irregular enhancement on CT and low T2 signal areas on MR. Necrosis is less common than SCC because adenocarcinomas generally grow more slowly and do not keratinize. Intense enhancement in metastases from hypervascular tumors (thyroid papillary carcinoma, RCC) results from tumor cells carrying rich vascular networks. Virchow node involvement represents retrograde lymphatic spread to the lymph node at the thoracic duct drainage point to the left venous angle.
Enlarged lymph node in left supraclavicular fossa is a classic clinical and radiological finding indicating distant metastasis of abdominal malignancy (gastric, pancreatic, colorectal, ovarian). Located at thoracic duct drainage point to left venous angle and represents retrograde lymphatic spread.
Round, solid, homogeneously or mildly heterogeneously enhancing lymph node on contrast-enhanced CT. Hilum is lost. Enhancement degree depends on primary tumor vascularity — intense in thyroid/RCC metastasis, moderate in colorectal/pancreatic. Short axis >10 mm (cervical), >8 mm (retropharyngeal), >15 mm (jugulodigastric) are diagnostic threshold values.
Report Sentence
Round lymph node with lost hilum, ... mm short axis, with solid enhancement in ... region, consistent with metastatic lymphadenopathy.
Round, hypoechoic lymph node with lost echogenic hilum. Short axis/long axis ratio >0.5 (rounding). Cortical thickening may be asymmetric and focal — early metastasis finding. Mixed echogenicity, heterogeneous internal structure. Capsule irregularity may indicate ENE.
Report Sentence
Round, hypoechoic lymph node with lost echogenic hilum, consistent with metastatic lymphadenopathy — primary tumor site should be investigated.
Peripheral and aberrant vascularity on Color Doppler — hilar vascularity lost, replaced by capsular and subcapsular irregular vessels. Vascularity degree depends on primary tumor — markedly increased vascularity in hypervascular tumor metastases. RI is usually high (>0.7).
Report Sentence
Lymph node shows hilar vascularity loss with peripheral aberrant vascularity — consistent with metastatic lymphadenopathy.
Diffusion restriction on DWI — ADC values usually 0.7-1.0 × 10⁻³ mm²/s. ADC may be more heterogeneous in tumors with desmoplastic stroma (pancreatic, colorectal) — fibrosis areas show high, viable tumor shows low ADC. Intermediate-low signal on T2 (lower than SCC — desmoplastic stroma effect). Enhancement on post-contrast T1 varies by primary tumor.
Report Sentence
Lymph node shows diffusion restriction on DWI (ADC: ... × 10⁻³ mm²/s), consistent with metastatic lymphadenopathy.
Lymph node with focal FDG uptake on PET-CT — SUVmax varies depending on primary tumor and node size (usually 3-15). Simultaneous intense uptake at primary tumor site. FDG positivity may indicate metastasis even in nodes not meeting size criteria (micrometastasis). Uptake in distant nodal stations (M1 staging) changes prognosis and treatment plan.
Report Sentence
Focal FDG uptake (SUVmax: ...) in lymph node at ... region, consistent with metastatic lymphadenopathy in context of primary tumor.
Criteria
Mediastinal and hilar LAP most common. N1 (ipsilateral peribronchial/hilar), N2 (ipsilateral mediastinal), N3 (contralateral/supraclavicular). PET-CT standard for staging.
Distinct Features
Moderate-intense enhancement, necrosis not common. Short axis >10 mm diagnostic threshold. PET-CT provides metabolic assessment independent of size criteria.
Criteria
Ipsilateral axillary LAP most common (30-40%). Internal mammary, supraclavicular, and infraclavicular stations may also be involved. Sentinel lymph node biopsy is standard approach.
Distinct Features
Cortical thickening >3 mm on axillary US, round morphology, hilum loss. Diffusion restriction on MR. US-guided FNA provides high accuracy for axillary staging.
Criteria
Pericolic/perirectal, mesenteric, and retroperitoneal LAP. N1 (1-3 regional nodes), N2 (≥4 regional nodes). Supraclavicular (Virchow) node involvement is M1 staging.
Distinct Features
Short axis >5 mm suspicious in pericolic/mesenteric nodes. Irregular margins and heterogeneous enhancement. Low density in mucin-containing metastases (mucinous type). False-negative on PET-CT may occur in mucinous type.
Distinguishing Feature
Reactive LAP shows oval shape, preserved hilum, hilar vascularity, and uniform cortical thickening — adenocarcinoma metastasis shows round morphology, hilum loss, peripheral vascularity, and focal asymmetric cortical thickening.
Distinguishing Feature
NHL shows conglomerate LAP, sandwich sign, bilateral widespread involvement, and extranodal masses — adenocarcinoma metastasis shows limited involvement in primary drainage basin, solid enhancing nodes, and known primary tumor.
Distinguishing Feature
SCC metastasis shows prominent and frequent central necrosis, cystic change (HPV+), head-neck primary — adenocarcinoma metastasis shows less frequent necrosis, solid enhancement predominant, and primary usually lung/breast/GI.
Distinguishing Feature
Sarcoidosis shows bilateral symmetric hilar LAP, absence of necrosis, parenchymal lung involvement, and usually low FDG uptake — adenocarcinoma metastasis shows asymmetric, focal LAP with primary tumor correlation.
Urgency
urgentManagement
surgicalBiopsy
NeededFollow-up
specialist-referralWhen metastatic adenocarcinoma nodal involvement is detected, primary tumor investigation and multidisciplinary tumor board evaluation are required. Biopsy (FNA or core) with histological diagnosis and immunohistochemistry (CK7, CK20, TTF-1, CDX2 etc.) provides clues to primary tumor type and location. Staging is performed according to primary tumor — N category determines treatment plan. Sentinel lymph node biopsy is standard in breast and melanoma. PET-CT is valuable for whole-body staging but has limited sensitivity in mucinous tumors.
Metastatic adenocarcinoma lymph node involvement determines disease stage and treatment plan. Sentinel lymph node biopsy is the standard approach in breast cancer. Virchow node (left supraclavicular LAP) is an important clinical sign for abdominal malignancy. PET-CT is used for staging and treatment response assessment.